Published in Medical Letter on the CDC and FDA, February 5th, 2006
This proprietary catheter, which was codeveloped by Stereotaxis and Biosense Webster, recently received U.S. Food and Drug Administration (FDA) approval for use with the Stereotaxis Niobe magnetic navigation system. This expands applications of the Stereotaxis Niobe System in the U.S. from diagnostic and device delivery procedures into the major therapeutic market for minimally invasive endocardial ablation treatment of cardiac arrhythmias.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.